Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 13;99(11):e19372. doi: 10.1097/MD.0000000000019372

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0

PMC Copyright notice

Kaplan–Meier estimates of PFS. (A) The median PFS for patients receiving chemotherapy or CCBT in the apatinib group was 10.1 mo compared with 6.4 mo for patients in the control group (log-rank test P < .01). (B) Stratified analyses revealed that the median PFS in patients who received chemotherapy was 10.1 mo in the apatinib group and 6.4 mo in the control group. (C) Stratified analyses demonstrated that the median PFS in patients receiving CCBT was 10.3 mo in the apatinib group and 6.1 mo in the control group (log-rank test P < .01). (D) The median overall survival in the full analysis set was 14.7 mo for patients in the apatinib group compared with 12.8 mo in the control group (log-rank test P = .719). CCBT = concurrent chemo-brachytherapy, PFS = progression-free survival.